Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Stanford researchers have developed a modular system of Synthetic cytokine receptors (SCRs), which are customizable receptors that mimic cytokine signals to precisely control immune cell behavior without the need for external cytokines.